Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Genelux Corporation before investing.

In this article, we go over a few key elements for understanding Genelux Corporation’s stock price such as:

• Genelux Corporation’s current stock price and volume
• Why Genelux Corporation’s stock price changed recently
• Upgrades and downgrades for GNLX from analysts
• GNLX’s stock price momentum as measured by its relative strength

About Genelux Corporation (GNLX)

Before we jump into Genelux Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Want to learn more about Genelux Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Genelux Corporation.

Genelux Corporation’s Stock Price as of Market Close

As of September 09, 2026, 11:11 AM, CST, Genelux Corporation’s stock price was $2.515.

Genelux Corporation is down 0.98% from its previous closing price of $2.540.

During the last market session, Genelux Corporation’s stock traded between $2.500 and $2.540. Currently, there are approximately 44.96 million shares outstanding for Genelux Corporation.

Genelux Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Genelux Corporation Stock Price History

Genelux Corporation’s (GNLX) price is currently down 3.82% so far this month.

During the month of September, Genelux Corporation’s stock price has reached a high of $2.660 and a low of $2.390.

Over the last year, Genelux Corporation has hit prices as high as $8.535 and as low as $2.290. Year to date, Genelux Corporation’s stock is down 42.32%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Genelux Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 08, 2026, there were 0 analysts who downgraded Genelux Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Genelux Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Genelux Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Genelux Corporation (GNLX) by visiting AAII Stock Evaluator.

Relative Price Strength of Genelux Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 08, 2026, Genelux Corporation has a weighted four-quarter relative price strength of -10.90%, which translates to a Momentum Score of 22 and is considered to be Weak.

Want to learn more about how Genelux Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Genelux Corporation Stock Price: Bottom Line

As of September 9, 2026, Genelux Corporation’s stock price is $2.515, which is down 0.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Genelux Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.